Clinical Validation of the Abbott RealTi m e High Risk HPV Assay According to the Guidelines for Human Papillomavirus DNA Test Requirements for Cervical Screening | Zendy

Albertus T. Hesselink | Zendy; Chris J.L.M. Meijer | Zendy; Mario Poljak | Zendy; Johannes Berkhof | Zendy; Folkert J. van Kemenade | Zendy; M. L. van der Salm | Zendy; Martijn Bogaarts | Zendy; Peter J.F. Snijders | Zendy; Daniëlle A.M. Heideman | Zendy

Open Access

Clinical Validation of the Abbott RealTi m e High Risk HPV Assay According to the Guidelines for Human Papillomavirus DNA Test Requirements for Cervical Screening

Author(s) -

Albertus T. Hesselink,

Chris J.L.M. Meijer,

Mario Poljak,

Johannes Berkhof,

Folkert J. van Kemenade,

M. L. van der Salm,

Martijn Bogaarts,

Peter J.F. Snijders,

Daniëlle A.M. Heideman

Publication year - 2013

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.00633-13

Subject(s) - human papillomavirus , cervical cancer , gynecology , medicine , dna testing , papillomaviridae , virology , oncology , cancer , biology , genetics

This study showed that the Abbott RealTim e High Risk HPV assay fulfilled cross-sectional clinical equivalence and reproducibility criteria of international consensus guidelines, which indicates that this assay can be considered clinically validated for cervical cancer screening purposes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research